Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Posts Tagged ‘genome’

Personal Genome Diagnostics Inc. announced a strategic collaboration with Mayo Clinic

Posted by fidest press agency su venerdì, 10 gennaio 2020

The two organizations have a shared vision for advancing the capabilities of oncology diagnostics and treatment. This collaboration will combine world-class clinical knowledge and expertise in oncology from Mayo Clinic with leadership in genomic technologies from PGDx to accelerate solutions that deliver on the promise of precision medicine.“We are proud to enter into this strategic collaboration with Mayo Clinic. Their deep knowledge of establishing standards of care in oncology, the complexity and volume of cancer cases they see, and their expertise in the implementation of testing in a real-world setting are second to none,” says Doug Ward, CEO, PGDx. “As we continue our quest to empower the fight against cancer, collaborating with Mayo Clinic will allow us to better assess the impact that our elio liquid biopsy and tissue applications will have on improving clinical insights, and will advance innovations in next-generation sequencing technology.” The shared vision and overall goal for PGDx and Mayo Clinic is to improve patient care by advancing the capabilities of oncology diagnostics testing. With a focus on targetable genomic alterations, this collaboration will take advantage of the clinical and technology expertise of both organizations.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The Launch of Cancer Whole Genome Sequencing Services

Posted by fidest press agency su sabato, 16 novembre 2019

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis’ Cancer Whole Genome Sequencing which further. Personalis’ portfolio of comprehensive cancer genomics services designed to maximize biological insights from tumor samples.“This new offering continues our push to provide our customers genomics solutions that enable deeper insights into patient responses to oncology therapies,” said John West, CEO of Personalis. “We are uniquely poised to provide a leading cancer whole genome sequencing solution which combines Personalis’ deep technology and experience in analyzing cancer samples for biopharma oncology clinical trials and the large-scale laboratory and data systems developed for the VA MVP program, one of the largest whole genome sequencing programs in the world.” Earlier this year, Personalis was awarded a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA Million Veteran Program (VA MVP). This order brought the cumulative scale of orders received to date from the VA MVP to over 110,000 human genomes. Since 2013, Personalis has sequenced over 40,000 MVP samples. Personalis anticipates it will sequence the additional samples over the coming years as they are received from the VA.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Goldfinch Bio Presents Methods to Mitigate Batch Effects in Whole Genome Sequencing

Posted by fidest press agency su giovedì, 24 ottobre 2019

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced a novel computational approach applied to its proprietary Kidney Genome Atlas (KGA) to enable a well-calibrated dataset for case-controlled genomic-wide association studies (GWAS) in focal segmental glomerulosclerosis (FSGS). These methods were described in an oral presentation on October 19th at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, TX.Researchers utilized the KGA, which currently contains whole genome sequencing (WGS) on 23,000 de-identified individual patients, including 2,000 cases of FSGS and other proteinuric disorders, to discover loci associated with FSGS, a disease that causes scarring of the kidney which can lead to kidney failure. The researchers sourced cases and controls from five clinical sites and 21 publicly-available cohort studies. The heterogeneity in sample acquisition presented challenges for downstream analysis, as evidenced by massive inflation in test statistics when standard filtering and quality control methods were applied. Notably, the data revealed a batch effect confounded with case/control status.Researchers then implemented a three-pronged data-driven approach to further determine and control for batch effects: identifying clusters of similar sequencing technologies by conducting a principal component analysis on depth of coverage; implementing a novel use of silhouette scores and permutations to quantify case-control dissimilarity at the dataset-level; and iteratively removing controls with high dissimilarity from cases to achieve a better-calibrated dataset for case-control GWAS.
A preliminary, proof-of-principle analysis in a subset of individuals showed that inflation was well controlled. After confirming the statistical associations, researchers will link the signals to specific genes to identify putative targets for therapeutic intervention.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The “Genome Editing/Genome Engineering – Market Analysis, Trends, and Forecasts”

Posted by fidest press agency su mercoledì, 14 agosto 2019

Genome Editing/Genome Engineering market worldwide is projected to grow by US$5.7 Billion, guided by a compounded growth of 14.6%.Staying on top of trends is essential for decision makers to leverage this emerging opportunity. The report addresses this very need and provides the latest scoop on all major market segments.CRISPR, one of the segments analyzed and sized in this study, displays the potential to grow at over 15.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.6 Billion by the year 2025, CRISPR will bring in healthy gains adding significant momentum to global growth.While global megatrends sweeping through the market influence the primary direction of growth, regional markets are swayed by more granular locally unique business drivers. Representing the developed world, the United States will maintain a 17.8% growth momentum.
Within Europe, which continues to remain an important element in the world economy, Germany will add over US$443.9 Million to the region’s size and clout in the next 5 to 6 years. Over US$438.5 Million worth of projected demand in the region will come from other emerging Eastern European markets.In Japan, CRISPR will reach a market size of US$235.6 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 13.6% over the next couple of years and add approximately US$928.9 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Professioni del futuro: da Statale e Politecnico in arrivo il “genome data scientist”

Posted by fidest press agency su domenica, 23 giugno 2019

L’Università degli Studi di Milano e il Politecnico di Milano lanciano a partire dal prossimo anno accademico il corso di Laurea Magistrale in Bioinformatics for Computational Genomics, due anni di studio interamente in inglese per fornire avanzate competenze informatiche e ingegneristiche finalizzate all’organizzazione e all’analisi di dati genomici ottenuti attraverso lo studio della biologia cellulare, molecolare, genetica e biochimica.L’introduzione di nuove tecnologie di analisi genomica ed epigenomica, tra le quali spicca il sequenziamento di nuova generazione (NGS), ha infatti rivoluzionato le metodologie di analisi in tutti gli ambiti delle scienze della vita, aprendo ai ricercatori possibilità inimmaginabili fino a pochi anni fa. Grazie a queste tecnologie è possibile ottenere una enorme mole di dati molecolari, la cui gestione e analisi è una delle più grandi sfide nell’ambito big data che l’umanità abbia mai affrontato, di fondamentale importanza per rispondere a domande biologiche di crescente complessità e per comprendere i processi fondamentali alla base della vita, sia in condizioni normali sia patologiche.
“I laureati saranno in grado di affrontare autonomamente le problematiche derivanti dalle moderne scienze biomolecolari quali genomica, trascrittomica, epigenomica e biologia dei sistemi”, spiega Giulio Pavesi, docente di Bioinformatica al Dipartimento di Bioscienze dell’Università Statale e coordinatore del corso. “Una figura professionale di questo tipo è già attualmente molto richiesta nell’ambito della ricerca pubblica, privata, di base e applicata, e i nuovi laureati potranno soddisfare la domanda crescente prevista per i prossimi anni, anche alla luce delle realtà che saranno sviluppate nell’area di Milano, prima tra tutte lo Human Technopole”, conclude Pavesi.“Il Corso di Laurea Magistrale è aperto sia a laureati in discipline computazionali, tra cui i laureati triennali in Ingegneria, sia a laureati in discipline biologiche e biotecnologiche, con un primo semestre diversificato” spiega Marco Masseroli, docente di Bioinformatica del Politecnico di Milano. “Sarà il primo in Italia e uno dei pochissimi in Europa e nel mondo a formare ‘data scientists’ con un profilo realmente multidisciplinare, sempre più richiesti nel mondo del lavoro. Saranno capaci di utilizzare al meglio le più avanzate tecnologie dell’informazione e del ‘machine learning’ per gestire e analizzare i ‘big data’ prodotti dalle moderne biotecnologie. Potranno, tra l’altro, contribuire alla medicina di precisione, ovvero alla determinazione di trattamenti individualizzati in base al profilo genetico dei pazienti”.Ha commentato il Rettore della Statale Elio Franzini: “Questa laurea magistrale rappresenta molto felicemente quanto la strada della collaborazione tra discipline e competenze specialistiche di alto livello ma fino a pochi anni fa considerate lontanissime tra loro, sia preziosa per rispondere alle sfide del futuro, in uno scenario scientifico, medico e sociale in rapidissima evoluzione. In questo senso la partnership tra Università Statale e Politecnico di Milano segna un traguardo di grande rilievo, per i nostri studenti e per la nostra città.” “Non c’è dubbio che lo studio del genoma sia tra le più grandi scommesse di tutti i tempi. – aggiunge Ferruccio Resta, Rettore del Politecnico di Milano – L’uso dei big data e delle tecniche di machine learning consentono infatti un’importante accelerazione che, tuttavia, dobbiamo sapere gestire. Un’ampia quantità di informazioni non è necessariamente sinonimo di un vantaggio o di una risposta funzionale ai problemi. Per questo abbiamo bisogno di unire competenze diverse: quella del biologo, che traccia la direzione, e quelle dell’ingegnere, che conosce a fondo le tecniche computazionali. È solo adottando un approccio interdisciplinare che possiamo rispondere a domande di crescente complessità. Ed è per questo che il Politecnico di Milano e l’Università degli Studi di Milano hanno deciso di fare squadra, di unire le proprie eccellenze, di rivolgere lo sguardo in avanti ai bisogni della ricerca e alle richieste del mercato.”
Le lezioni si svolgeranno in Statale presso Città Studi e al Politecnico in piazza Leonardo da Vinci. Per l’anno 2019/2020 sono disponibili 50 posti (oltre ad altri 10 riservati a cittadini extra UE). Le domande di ammissione vanno presentate entro il 10 luglio, mentre la prova di ammissione si svolgerà il 16 luglio. Tutte le informazioni sono contenute nel bando e nel sito dedicato.

Posted in Università/University | Contrassegnato da tag: , , , | Leave a Comment »

Incorporate genome sequencing into its consumer health intelligence service

Posted by fidest press agency su sabato, 9 febbraio 2019

Onegevity Health, a new consumer health intelligence company, announced a partnership with Gencove, a leader in genome sequencing and analytics, to incorporate genome sequencing into its consumer health intelligence service.Gencove will provide its cost-effective and scalable low-pass sequencing technology to support Onegevity Health’s multi-omic artificial intelligence (AI) platform, consumer-friendly products, and digital services.
Onegevity Health delivers science-based recommendations for customized nutrition, clinically-studied supplements, and pre- and post-biotics to improve health outcomes. The company’s first product, GutBioTM, combines its advanced Metagenome+TM sequencing technology with AI-based personalized insights and recommendations to help individuals manage and improve gut health. The partnership with Gencove will allow it to expand its offering to include genome sequencing.Onegevity Health was founded by scientific pioneers Drs. Joel Dudley and Chris Mason, along with Thorne CEO Paul Jacobson. The partnership with Thorne will leverage the company’s network of 35,000 physicians. Gencove was founded by leading scientists from the New York Genome Center.Gencove and Onegevity Health also plan to leverage the growing multi-omics database for research and therapeutic development. Compared to other commonly used technologies in direct-to-consumer genomics such as genotyping arrays, Gencove’s low-pass sequencing will integrate whole genome data, which in turn will accelerate research on rare genetic variants and early-stage drug target discovery.
According to Jacobson, “Gencove’s low-pass sequencing technologies provide us with the opportunity to apply genome sequencing at the scale necessary to truly impact population health and also ensure the greatest capacity to integrate future discoveries in all areas of the genome, from known genes to novel non-coding RNAs to regulatory regions, all of which are missed by vendors using arrays or exome capture. Also, genome-microbiome interactions can only truly be modeled by having such integrated data sets from each person.”Joe Pickrell, CEO and co-founder of Gencove, added, “We are excited to support the scientific vision of Onegevity Health and its mission to improve consumer wellness.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Basic cardiovascular science congress set to stimulate public discussion on genome editing

Posted by fidest press agency su martedì, 27 marzo 2018

Vienna, Austria 20 to 22 April. The European Society of Cardiology’s (ESC) basic science congress is set to stimulate public discussion on the use of genome editing and other cutting edge technologies to prevent cardiovascular disease.Frontiers in CardioVascular Biology (FCVB) 2018 is organised by the Council on Basic Cardiovascular Science of the ESC in collaboration with 12 European cardiovascular science societies. It will be held from 20 to 22 April at the Austria Centre Vienna. The full scientific programme is available here.Germline genome editing, which is performed in either the oocyte or sperm, could be used to prevent disease – for example hypertrophic cardiomyopathy, which is caused by a mutation in the MYBPC3 gene. It could also be used to reduce the risk of coronary heart disease by, for example, introducing a loss-of-function in the PCSK9 gene, thereby interfering with cholesterol levels. Another application could be to introduce advantageous or otherwise desirable traits such as athletic ability.Tissue engineering will also be explored at the congress. The technique could be used in patients with end-stage heart failure by growing a patch of healthy cells outside the body and then implanting it into the damaged area of the heart to support its pump function.Experts will present the latest data linking gut bacteria and their metabolites with health and disease. Certain combinations have been associated with atherosclerosis, hypertension, type 2 diabetes, and heart failure.
Leaders in the field of cell therapy, in which stem cells or progenitor cells are injected into the patient to repair a damaged heart, will explore the pros and cons of this technique and discuss why meta-analyses of randomised trials assessing cell therapy to promote cardiac repair in myocardial infarction have reported conflicting results.Professor Wojta said: “Another issue is that the results of cell therapy have been promising in animal models but modest in humans. One explanation is that we have used young, healthy animals with artificially induced myocardial infarction whereas patients are older, unhealthy, and have developed coronary heart disease over years or decades until experiencing a myocardial infarction.”He concluded: “Cell therapy is an area of research in which we moved very quickly from the bench to the bedside. We need to go back to the bench and come up with more relevant animal models that could give us better solutions for use in humans.”

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Eone-Diagnomics Genome Center (EDGC) Attracts Investment from Lock & Lock Chairman, Kim Joon-il

Posted by fidest press agency su mercoledì, 27 dicembre 2017

Hong Kong. Eone-Diagnomics Genome Center (EDGC), a global genetic analysis company, announced that it has raised private equity investment from Kim Joon-il, the Chairman of Lock & Lock.Chairman Kim founded Lock & Lock in 1978, and it has since grown into a global kitchenware company, exporting to more than 100 countries around the world. In August 2017, Kim decided to sell his entire stake to Hong Kong private equity firm Affinity Equity Partners. Kim, as his first reinvestment of proceeds from the sale of his Lock & Lock’s stake, has chosen to make an investment in EDGC. He firmly believes in EDGC’s potential to lead the 4th industrial revolution through its technology.
EDGC provides customized medical services based both on next generation sequencing (NGS) and genotyping techniques along with cutting-edge genome analysis. It continues to develop new medical products and services, including early-onset cancer diagnosis (gene2me™Plus), non-invasive prenatal test (NICE®), newborn genetic screening (bebegene®), ophthalmologic genetic screening (myeyegene™), and direct-to-consumer (DTC) genetic testing (gene2me™). In recent years, EDGC has applied machine learning-based Artificial Intelligence (AI) technology to its non-invasive prenatal testing NICE®. In the field of liquid biopsy, EDGC is currently conducting clinical trials with major domestic universities and hospitals.EDGC’s rapid growth and market-generating ability have attracted the attention of domestic and international industries. It has been included as the only Asian company in Illumina’s Global Screening Array (GSA), the largest international genomics consortium in the world; the initial customer includes human disease researchers at The Broad Institute, Sanford Health and UCLA Health System and consumer genomics company 23andMe.”As we have attracted significant investment, we will continue to contribute to improvement of health and happiness of the world,” said Shang Cheol Shin, CEO of EDGC.Kim Joon-il added, “As the first step of reinvesting the stake in Lock & Lock, we have made an effort to select the investment destination more strictly. I am convinced that EDGC technology advances every facet of life and will continue to permeate various industrial sectors.”

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »